Creatine is best known as a sports supplement, but the same chemistry that helps muscle contract—rapid energy buffering via the creatine/phosphocreatine system—also operates in the brain.

Neurons have intense and fluctuating energy needs, and creatine kinase enzymes help keep ATP (the cell’s “energy currency”) available when demand spikes.

That bioenergetic rationale is why creatine has become a candidate “nutritional nootropic”: not a stimulant in the caffeine sense, but a potential support for memory, attention, and mental stamina—especially when the brain is under strain.

What does the clinical literature actually show? Over the last few years, the evidence has sharpened into a consistent, if modest, picture: creatine can improve some cognitive outcomes in some contexts, but it is not a universal cognitive booster.

The strongest signals tend to appear in specific groups (for example, older adults or people with illness) or under metabolic stress (such as sleep deprivation), while well-rested young adults often show little to no benefit.

A brain supplement that actually reaches the brain

One practical question sits at the center of creatine’s nootropic story: can oral creatine meaningfully raise brain creatine stores?

A key point is that brain uptake is constrained by transporters at the blood–brain barrier, so changes can be smaller and slower than in muscle. Still, magnetic resonance spectroscopy studies indicate that brain creatine can rise measurably.

A frequently cited human study reported an 8.7% increase in brain creatine after 4 weeks of 20 g/day supplementation (Dechent et al. 1999, discussed in (Sandkühler et al. 2023)).

This matters because it supports a plausible mechanism: if brain creatine stores are even slightly higher, the phosphocreatine “buffer” may better stabilize energy supply during demanding cognition—particularly tasks that rely heavily on the prefrontal cortex and rapid information processing.

What the meta-analyses say

Two recent quantitative reviews help anchor expectations.

A 2024 systematic review and meta-analysis of randomized trials in adults (16 RCTs; N=492) found statistically significant benefits in several specific domains (Xu et al. 2024):

• Memory: standardized mean difference (SMD) 0.31 (95% CI 0.18 to 0.44)
• Attention time: SMD −0.31 (95% CI −0.58 to −0.03)
• Processing speed time: SMD −0.51 (95% CI −1.01 to −0.01)

However, the same analysis found no significant improvement in overall cognitive function or executive function, and rated evidence certainty as moderate for memory but low for several other outcomes (Xu et al. 2024).

A separate 2023 meta-analysis focused specifically on memory in healthy individuals found an overall improvement but emphasized heterogeneity and subgroup dependence.

Across included RCTs, creatine improved “overall memory” with SMD 0.29 (95% CI 0.04 to 0.53; I²=66%; P=0.02). Notably, the effect looked larger in older adults (66–76 years: SMD 0.88, 95% CI 0.22 to 1.55; P=0.009) while being essentially absent in younger adults (11–31 years: SMD 0.03; P=0.72) (Prokopidis et al. 2023).

Taken together, these meta-analyses support a realistic framing: creatine’s cognitive effects, when present, are typically modest and domain-specific, not a broad upgrade to “IQ” or executive function for everyone.

Vegetarians

Some of creatine’s popularity as a “brain supplement” traces back to an influential early trial in vegetarians. In a double-blind, placebo-controlled cross-over study, 45 young adult vegetarian participants took 5 g/day for 6 weeks, and creatine significantly improved both working memory (backward digit span) and reasoning (Raven’s Advanced Progressive Matrices) with p < 0.0001 (Rae et al. 2003).

More recently, a much larger and methodologically careful attempt to replicate and broaden those findings produced a more tempered result. In a preregistered, double-blind, placebo-controlled cross-over RCT with 123 participants (about half vegetarians, half omnivores), using the same 5 g/day for 6 weeks, creatine’s estimated effects were small:

• Backward Digit Span: +0.41 correct items (about a 0.2-digit longer span); Cohen’s d = 0.17
• Raven’s matrices: +0.23 matrices solved; Cohen’s d = 0.09

The authors described this as “some indication” for working memory but not a robust cognitive transformation (Sandkühler et al. 2023).

This pair of studies illustrates a pattern that shows up repeatedly in the literature: early, striking effects (especially in small samples and specific diets) often shrink when tested in larger, more diverse cohorts.

When creatine looks most like a nootropic: cognitive stress and sleep loss

Where creatine becomes most interesting—scientifically and practically—is under conditions that tax brain energy metabolism.

A recent example is a randomized, double-blind cross-over study in 15 healthy young adults undergoing ~21 hours of sleep deprivation, where participants received a single high oral dose of creatine (0.35 g/kg) or placebo.

Creatine partially reversed fatigue-related cognitive deterioration and improved multiple measures (Gordji-Nejad et al. 2024). Reported effects versus placebo included:

• Subjective fatigue (FAT): reduced by 8 ± 7% (p=0.002) when pooled at 2 a.m. and 4 a.m.
• Word Memory Test (WMT) accuracy: +10.3 ± 3.8% (p=0.005)
• Processing speed improvements (time reductions) pooled across late-night testing:
  • Language task: 29.1 ± 5.3% (p=2.0×10⁻⁶)
  • Logic task: 16.0 ± 4.0% (p=0.0002)
  • Numeric task: 24.0 ± 4.9% (p=1.02×10⁻⁵)

Importantly, the study paired cognitive tests with brain spectroscopy markers consistent with altered high-energy phosphate metabolism during sleep deprivation (Gordji-Nejad et al. 2024).

Earlier sleep-deprivation work also points in the same direction. In one double-blind study (creatine n=10, placebo n=9) using 20 g/day for 7 days, creatine reduced performance decrements after 24 hours of sleep deprivation on tasks such as random movement generation and choice reaction time, and improved mood measures (McMorris et al. 2006).

This “stress-dependent” profile is echoed by a 2024 systematic review arguing that while creatine can increase brain creatine content, cognitive benefits are clearer in stressed populations and often minimal in non-stressed groups (McMorris et al. 2024).

When creatine does not behave like a nootropic

If you test well-rested young adults with a broad cognitive battery, results are often null.

For example, in a double-blind placebo-controlled study of 22 young adults (21 ± 2 years) taking creatine 0.03 g/kg/day for 6 weeks, there were no significant effects across reaction time, code substitution, reasoning, math processing, and memory tasks (all p > 0.05) (Rawson et al. 2008).

These findings help explain why creatine’s “brain booster” reputation can feel inconsistent in real life: for many healthy, non-sleep-deprived people, any cognitive effect may be too small to notice subjectively.

Creatine’s neurological footprint in clinical research extends beyond healthy cognition.

• Alzheimer’s disease (pilot feasibility): In a single-arm study of 20 patients given 20 g/day for 8 weeks, brain total creatine increased by 11% (p < .001) and multiple cognitive test scores improved (for example, global composite p=0.02, fluid composite p=0.004). Because there was no placebo group, this is best read as feasibility plus a signal worth testing in larger RCTs, not proof of efficacy (Smith et al. 2025).
• Depression augmentation (mechanism-relevant to cognition): In an 8-week RCT of 52 women receiving escitalopram plus creatine (5 g/day; n=25) or placebo (n=27), symptom reduction was faster and larger with creatine. By week 2, mean HAM-D was 14.7 in the creatine group vs 20.3 placebo (Cohen’s d 1.28), and by week 8 it was 5.4 vs 9.8; remission at week 8 was 52.0% vs 25.9% (Lyoo et al. 2012). Mood changes are not cognition per se, but improved depression can indirectly affect attention and memory in day-to-day functioning.
• Parkinson’s disease (large negative trial): A major phase 3 trial in 1741 people with early treated Parkinson’s disease tested creatine 10 g/day for at least 5 years and was stopped early for futility. In the interim cohort (n=955), the global outcome showed no benefit (mean summed ranks 2414 creatine vs 2360 placebo; P=0.45) (NET-PD LS-1; publication 2015). This doesn’t directly answer “nootropic creatine,” but it is a sobering reminder that plausible bioenergetics don’t automatically translate into meaningful clinical or functional outcomes.
• Traumatic brain injury (pediatric pilot): An open-label randomized pilot in 39 children/adolescents used creatine 0.4 g/kg/day for 6 months and reported improvements across multiple functional and cognitive categories, with several domains showing p-values as low as <0.001 (Sakellaris et al. 2006). The design is preliminary, but it aligns with the broader hypothesis that creatine may matter most when the brain is metabolically stressed or injured.

Creatine as a nootropic

• Creatine is biologically plausible as a cognitive enhancer because it supports brain energy buffering and can raise brain creatine modestly.
• The best-supported cognitive benefits are small-to-moderate improvements in memory and sometimes processing speed/attention time, with meta-analytic estimates around SMD ~0.3 in targeted outcomes (Xu et al. 2024; Prokopidis et al. 2023).
• Effects appear most consistent in older adults and conditions of cognitive stress (sleep deprivation, possibly hypoxia), while well-rested young adults frequently show no measurable improvement (Rawson et al. 2008; McMorris et al. 2024).
• Large trials in some neurological diseases have been negative (NET-PD LS-1 in Parkinson’s), so creatine should not be treated as a general “neuroprotective” therapy without condition-specific evidence.

References

Dechent, P., Pouwels, P. J. W., Wilken, B., Hanefeld, F., & Frahm, J. (1999). Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. American Journal of Physiology – Regulatory, Integrative and Comparative Physiology, 277(3), R698–R704. https://pubmed.ncbi.nlm.nih.gov/10484486/

Gordji-Nejad, A., Matusch, A., Kleedörfer, S., Patel, H. J., Drzezga, A., Elmenhorst, D., Binkofski, F., & Bauer, A. (2024). Single dose creatine improves cognitive performance and induces changes in cerebral high energy phosphates during sleep deprivation. Scientific Reports, 14, 4937. https://www.nature.com/articles/s41598-024-54249-9

Kieburtz, K., et al. (NINDS NET-PD LS-1 Investigators). (2015). Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: A randomized clinical trial. JAMA. https://pubmed.ncbi.nlm.nih.gov/25668262/

Lyoo, I. K., et al. (2012). A Randomized, Double-Blind Placebo-Controlled Trial of Oral Creatine Monohydrate Augmentation for Enhanced Response to a Selective Serotonin Reuptake Inhibitor in Women With Major Depressive Disorder. American Journal of Psychiatry. https://pmc.ncbi.nlm.nih.gov/articles/PMC4624319/

McMorris, T., Harris, R. C., Swain, J., Corbett, J., Collard, K., Dyson, R. J., & Draper, N. (2006). Effect of creatine supplementation and sleep deprivation, with mild exercise, on cognitive and psychomotor performance, mood state, and plasma concentrations of catecholamines and cortisol. Psychopharmacology (Berl), 185(1), 93–103. https://pubmed.ncbi.nlm.nih.gov/16416332/

McMorris, T., et al. (2024). Creatine supplementation research fails to support the theoretical basis for an effect on cognition: Evidence from a systematic review. Behavioural Brain Research, 466, 114982. https://pubmed.ncbi.nlm.nih.gov/38582412/

Prokopidis, K., Giannos, P., Triantafyllidis, K. K., Kechagias, K. S., & Forbes, S. C. (2023). Effects of creatine supplementation on memory in healthy individuals: a systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews, 81(4), 416–432. https://academic.oup.com/nutritionreviews/article/81/4/416/6671817

Rae, C., Digney, A. L., McEwan, S. R., & Bates, T. C. (2003). Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial. Proceedings of the Royal Society B, 270(1529), 2147–2150. https://pubmed.ncbi.nlm.nih.gov/14561278/

Rawson, E. S., Lieberman, H. R., & Walsh, T. M. (2008). Creatine supplementation does not improve cognitive function in young adults. Physiology & Behavior, 95(1–2), 130–134. https://pubmed.ncbi.nlm.nih.gov/18579168/

Sakellaris, G., Kotsiou, M., Tamiolaki, M., Kalama, M., & Kouskoukis, A. (2006). Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration: an open label randomized pilot study. Journal of Trauma. https://pubmed.ncbi.nlm.nih.gov/16917445/

Sandkühler, J. F., et al. (2023). The effects of creatine supplementation on cognitive performance—a randomised controlled study. BMC Medicine, 21, 411. https://link.springer.com/article/10.1186/s12916-023-03146-5

Smith, A. N., et al. (2025). Creatine monohydrate pilot in Alzheimer’s: Feasibility, brain creatine, and cognition. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. https://pubmed.ncbi.nlm.nih.gov/40395689/

Xu, C., Bi, S., Zhang, W., & Luo, L. (2024). The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis. Frontiers in Nutrition, 11, 1424972. https://pubmed.ncbi.nlm.nih.gov/39070254/